FdaApplication
NDA 202714
Identifiers
- fda_app_no: NDA202714
Properties
| Property | Value |
|---|---|
| applicant_name | ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC |
| application_type | NDA |
| approval_date | 2012-07-20 |
Revenue by product
KYPROLIS
| Period | Revenue |
|---|---|
| Q2 2026 | $314.0M |
| Q1 2026 | $330.0M |
| Q3 2025 | $359.0M |
| Q2 2025 | $378.0M |
| Q1 2025 | $324.0M |
| Q4 2024 | $372.0M |
| Q3 2024 | $378.0M |
| Q2 2024 | $377.0M |
| Q1 2024 | $376.0M |
| Q4 2023 | $350.0M |
| Q3 2023 | $349.0M |
| Q2 2023 | $346.0M |
| Q1 2023 | $358.0M |
| Q4 2022 | $325.0M |
| Q3 2022 | $318.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KYPROLIS | CARFILZOMIB | 10MG/VIAL | POWDER;INTRAVENOUS |
| KYPROLIS | CARFILZOMIB | 60MG/VIAL | POWDER;INTRAVENOUS |
| KYPROLIS | CARFILZOMIB | 30MG/VIAL | POWDER;INTRAVENOUS |
3 products